Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias.

Cancer Res Treat · 2024 · PMC11261188 · PMID 38186241

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

showed a trendp=0.17not close (p > 0.1)

After irAEs were resolved, ICI resumption showed a trend towards improved PFS (12.1 vs. 7.9 months, p=0.17) and OS (27.5 vs. 18.0 months, p=0.73) ( Fig. 3 ). 7.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.